Compositions and methods for treatment of cachexia

Details Compositions and methods for treatment of cachexia Compositions and methods for treatment of cachexia

2006-12-20

2011-12-20

Peselev, Elli (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

08080528

ABSTRACT:
Compositions and methods for preventing and treating wasting disorders, such as cachexia and anorexia, are provided. In one aspect, the present invention provides a method for preventing and treating a wasting disorder in a mammal. In one embodiment, the method of the invention comprises administering to such mammal a macrolide and a β2-adrenergic agonist in combination such that the macrolide and said β2-agonist are administered in amounts effective to prevent or at least alleviate said wasting disorder.

REFERENCES:
patent: 5750493 (1998-05-01), Sommadossi et al.
patent: 5880101 (1999-03-01), Stankov
patent: 7101576 (2006-09-01), Hovey et al.
patent: 0 308 157 (1989-03-01), None
patent: 0 338 404 (1989-10-01), None
patent: 2005/060693 (2007-07-01), None
patent: 2008/004224 (2008-01-01), None
MacDonald et al “Understanding and Managing Cancer Cachexia”, J. Am. Coll. Surg. vol. 197, No. 1, Jul. 2003, pp. 143-161.
Stallion et al “Reversal of cancer cachexia in rats by cimaterol and supplemental nutrition”, Surgery, Oct. 1991, vol. 110, No. 4, pp. 678-684 (Abstract).
Stallion et al, “Reversal of cancer cachexia in rats by cimaterol and supplemental nutrition”, Surgery, Oct. 1991, 110(4): 678-684.
Yavuzen, T., et al., “Systematic Review of the Treatment of Cancer-Associated Anorexia and Weight Loss”, J Clin Oncol 23.8500-8511 (2005).
Busquets, S., et al., “Anticachectic Effects of Formoterol: A Drug for Potential Treatment of Muscle Wasting”, [Cancer Research 64, 6725-6731, Sep. 15, 2004.
Easton-Carter, K.L., et al., “Possible Roxithromycin-Induced Fulminant Hepatic Failure in a Child”, Pharmacotherapy 2001;21(7):867-870.
Pirzada, O.M., et al., “Improved lung function and body mass index associated with long-term use of Macrolide antibiotics”, Journal of Cystic Fibrosis 2 (2003) 69-71.
Carbo, N., et al., “Comparative effects of b2-adrenergic agonists on muscle waste associated with tumour growth”, Cancer Letters 115 1997 113-118.
Sakamoto, M., et al., “Long-term clarithromycin treatment for cancer cachexia of inoperable non-small cell lung cancer patients”, Japanese Journal of Chemotherapy, vol. 44, 1996. Abstract.
Sakamoto, M., et al., “Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer”, Chemotherapy, Dec. 2001.
Hori, S., et al., “Effect of clarithromycin on lipopolysaccharide-induced anorexia”, The Japanese journal of antibiotics, Dec. 2001.
Sakamoto, M., et al., “Efficacy of clarithromycin on cancer cachexia in patients with primary non-small cell lung cancer”, The Japanese journal of antibiotics, Mar. 1997.
Antonio Pascal Lopez, et al., “Systematic Review of megestrol acetate in the treatment of anorexia-cachexia syndrome”, J. Pain and Symptom Management 27(4):360-369 2004.
Main, B.W., et al., “Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propanolol or dobutamine, in consious unrestrained dogs”, J. Veterinary Pharmacology and Therapeutics 19:225-232 1996.
Extended European Patent Office Search Report, dated Oct. 30, 2009.

Affiliated with

Also associated with

Rating

Compositions and methods for treatment of cachexia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for treatment of cachexia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of cachexia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4296471